( en and ventilatory support canbe modif...)Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies,Health

en and ventilatory support can be modified to respond to respiratory changes. Physiological endpoints have not proven to impact key clinical outcomes such as mortality due to RDS. Clinical studies have not evaluated whether fewer doses or longer dosing intervals result in superior safety or efficacy based on clinically relevant endpoints. Transient adverse effects seen with administration of Curosurf(R) include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation

About Dey, L.P.

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the U.S. leader in nebulized respiratory medication, DEY puts patients first through its development of innovative and affordable therapies. The Web sites for DEY include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.duoneb.com, and http://www.epipen.com. Dey, L.P. is an affiliate of Merck KGaA, Darmstadt, Germany.

Curosurf is a registered trademark of Chiesi Farmaceutici, Parma, Italy.

Survanta is a registered trademark of Ross Product Division, Abbott Laboratories Inc.

    Infasurf is a registered trademark of Forest Pharmaceuticals, Inc.



    Media contacts:


    Dey, L.P. Media Line

    1-800-755-5560 ext. 8363

          or

    Harriet Ullman

    Feinstein Kean Healthcare

    617-761-6776

    


    Linda Storari

    Chiesi Farmaceutici SpA

    +39 0521 279 620

    

          or

    Massimo Zan
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Common Preterm Labor Drug Has More Side Effects Than Alternative,
Finds Study from Packard Childrens Hospital and Stanford
2. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab)
May Reduce Subsequent Recurrent Wheezing in Preterm Infants
3. Columbia Laboratories Reports Preliminary Findings from the Ongoing
Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%
(progesterone gel) to Prevent Preterm Birth
4. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of
Blindness in Premature Infants
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology
Shown to Significantly Lower Instances of Severe Retinopathy of
Prematurity in Extremely Low Birth Weight Infants
6. Alnylam Reports Results of Human Experimental Infection Model with
Respiratory Syncytial Virus
7. Baxter Presents Phase I Inhaled Insulin Study Results at
Respiratory Drug Delivery Conference
8. DVT Awareness Survey Findings: Heart and Respiratory Patients
9. Interim Data From RECORD Study Show No Significant Difference
Between Avandia and Standard Therapy in Risk of Cardiovascular
Hospitalization or Death
10. New Research Results Show That Investigational Drug Phenoxodiol
Targets Cancer Protein, Causing Cancer Cell Death
11. Landmark Findings From ECLIPSE Program Show Improved Control of
Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery